213 related articles for article (PubMed ID: 24787487)
1. Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.
Hiasa M; Teramachi J; Oda A; Amachi R; Harada T; Nakamura S; Miki H; Fujii S; Kagawa K; Watanabe K; Endo I; Kuroda Y; Yoneda T; Tsuji D; Nakao M; Tanaka E; Hamada K; Sano S; Itoh K; Matsumoto T; Abe M
Leukemia; 2015 Jan; 29(1):207-17. PubMed ID: 24787487
[TBL] [Abstract][Full Text] [Related]
2. Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.
Fujii S; Nakamura S; Oda A; Miki H; Tenshin H; Teramachi J; Hiasa M; Bat-Erdene A; Maeda Y; Oura M; Takahashi M; Iwasa M; Endo I; Yoshida S; Aihara KI; Kurahashi K; Harada T; Kagawa K; Nakao M; Sano S; Abe M
Br J Haematol; 2018 Jan; 180(2):246-258. PubMed ID: 29327347
[TBL] [Abstract][Full Text] [Related]
3. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.
Asano J; Nakano A; Oda A; Amou H; Hiasa M; Takeuchi K; Miki H; Nakamura S; Harada T; Fujii S; Kagawa K; Endo I; Yata K; Sakai A; Ozaki S; Matsumoto T; Abe M
Leukemia; 2011 Jul; 25(7):1182-8. PubMed ID: 21475253
[TBL] [Abstract][Full Text] [Related]
4. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.
Takeuchi K; Abe M; Hiasa M; Oda A; Amou H; Kido S; Harada T; Tanaka O; Miki H; Nakamura S; Nakano A; Kagawa K; Yata K; Ozaki S; Matsumoto T
PLoS One; 2010 Mar; 5(3):e9870. PubMed ID: 20360846
[TBL] [Abstract][Full Text] [Related]
5. Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.
Teramachi J; Hiasa M; Oda A; Harada T; Nakamura S; Amachi R; Tenshin H; Iwasa M; Fujii S; Kagawa K; Miki H; Kurahashi K; Yoshida S; Endo I; Haneji T; Matsumoto T; Abe M
Br J Haematol; 2018 Feb; 180(4):581-585. PubMed ID: 27748523
[No Abstract] [Full Text] [Related]
6. Targeting the Pim kinases in multiple myeloma.
Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
[TBL] [Abstract][Full Text] [Related]
7. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
[TBL] [Abstract][Full Text] [Related]
8. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2.
Sowa H; Kaji H; Hendy GN; Canaff L; Komori T; Sugimoto T; Chihara K
J Biol Chem; 2004 Sep; 279(39):40267-75. PubMed ID: 15150273
[TBL] [Abstract][Full Text] [Related]
9. Antimyeloma activity of the sesquiterpene lactone cnicin: impact on Pim-2 kinase as a novel therapeutic target.
Jöhrer K; Obkircher M; Neureiter D; Parteli J; Zelle-Rieser C; Maizner E; Kern J; Hermann M; Hamacher F; Merkel O; Wacht N; Zidorn C; Scheideler M; Greil R
J Mol Med (Berl); 2012 Jun; 90(6):681-93. PubMed ID: 22205266
[TBL] [Abstract][Full Text] [Related]
10. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
[TBL] [Abstract][Full Text] [Related]
11. An overview of pim kinase as a target in multiple myeloma.
Liu Z; Zhang Y; Guo Y; Wang H; Fu R
Cancer Med; 2023 May; 12(10):11746-11759. PubMed ID: 37162273
[TBL] [Abstract][Full Text] [Related]
12. TGF-β-related mechanisms of bone destruction in multiple myeloma.
Matsumoto T; Abe M
Bone; 2011 Jan; 48(1):129-34. PubMed ID: 20570621
[TBL] [Abstract][Full Text] [Related]
13. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
14. Requirement of BMP-2-induced phosphatidylinositol 3-kinase and Akt serine/threonine kinase in osteoblast differentiation and Smad-dependent BMP-2 gene transcription.
Ghosh-Choudhury N; Abboud SL; Nishimura R; Celeste A; Mahimainathan L; Choudhury GG
J Biol Chem; 2002 Sep; 277(36):33361-8. PubMed ID: 12084724
[TBL] [Abstract][Full Text] [Related]
15. Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.
Bolzoni M; Donofrio G; Storti P; Guasco D; Toscani D; Lazzaretti M; Bonomini S; Agnelli L; Capocefalo A; Dalla Palma B; Neri A; Nicolini F; Lisignoli G; Russo F; Colla S; Aversa F; Giuliani N
Leukemia; 2013 Feb; 27(2):451-63. PubMed ID: 22781592
[TBL] [Abstract][Full Text] [Related]
16. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451
[TBL] [Abstract][Full Text] [Related]
17. Bone morphogenetic protein receptor IB signaling mediates apoptosis independently of differentiation in osteoblastic cells.
Haÿ E; Lemonnier J; Fromigué O; Guénou H; Marie PJ
J Biol Chem; 2004 Jan; 279(3):1650-8. PubMed ID: 14576167
[TBL] [Abstract][Full Text] [Related]
18. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.
Standal T; Abildgaard N; Fagerli UM; Stordal B; Hjertner O; Borset M; Sundan A
Blood; 2007 Apr; 109(7):3024-30. PubMed ID: 17138824
[TBL] [Abstract][Full Text] [Related]
19. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
[TBL] [Abstract][Full Text] [Related]
20. Microarray analysis of bone morphogenetic protein, transforming growth factor beta, and activin early response genes during osteoblastic cell differentiation.
de Jong DS; van Zoelen EJ; Bauerschmidt S; Olijve W; Steegenga WT
J Bone Miner Res; 2002 Dec; 17(12):2119-29. PubMed ID: 12469906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
